BioCryst Pharmaceuticals, Inc. (BCRX) Posts Q4 Loss of 22c/Share
Tweet Send to a FriendGet Alerts BCRX Hot Sheet
Price: $1.71 -1.16%
EPS Growth %: +30.8%
Financial Fact:
Basic and diluted net loss per common share: -0.09
Today's EPS Names:
LBIX, ESEA, ISS, More
EPS Growth %: +30.8%
Financial Fact:
Basic and diluted net loss per common share: -0.09
Today's EPS Names:
LBIX, ESEA, ISS, More
Trade BCRX Now!
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q4 EPS of ($0.22), $0.06 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.02 million.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- Leading Brands Inc New (LBIX) Reports Breakeven Q4 Loss
- BioCryst (BCRX) Hit Traders' Radars Again as China Bird Flu Death Toll Jumps Nearly 10%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
